Comparative Pharmacology
Head-to-head clinical analysis: EDURANT versus ETRAVIRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDURANT versus ETRAVIRINE.
EDURANT vs ETRAVIRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to HIV-1 reverse transcriptase, causing conformational changes that inhibit enzyme activity and viral replication.
Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase, causing allosteric inhibition of RNA-dependent and DNA-dependent DNA polymerase activities.
25 mg orally once daily with a meal.
400 mg orally twice daily after meals.
None Documented
None Documented
Terminal half-life 38 hours (range 25-57 h); supports once-daily dosing, steady state at ~7 days
Clinical Note
moderateEtravirine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Etravirine."
Clinical Note
moderateEtravirine + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Etravirine."
Clinical Note
moderateEtravirine + Cyclosporine
"The serum concentration of Cyclosporine can be increased when it is combined with Etravirine."
Clinical Note
moderateEtravirine + Fluconazole
Terminal elimination half-life approximately 41 hours (range 20-70 hours) following multiple doses; supports once-daily dosing with a pharmacokinetic booster (e.g., ritonavir or cobicistat).
Renal (~25% unchanged) and fecal (~60% as metabolites); total recovery ~85%
Fecal: ~93.7% (unchanged drug and metabolites; bile is the major route); Renal: ~1.2% (urinary, negligible unchanged drug).
Category C
Category C
NNRTI Antiretroviral
NNRTI Antiretroviral
"The serum concentration of Fluconazole can be increased when it is combined with Etravirine."